Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
csDMARDs
Questions discussed in this category
Should MTX be avoided in RA patients with asymptomatic lung nodules?
If so, what would be an ideal DMARD in this setting?
1 Answer available
How long do you wait for response to corticosteroids and conventional synthetic DMARDs before considering IVIG in patients with HMGCR antibody positive IMNM?
1 Answer available
How does the presence of nonalcoholic fatty liver disease (NAFLD) impact your choice of csDMARD for RA?
1 Answer available
Should patients be screened for hepatitis B/C prior to starting a conventional synthetic DMARD such as methotrexate?
1 Answer available
8805
8467
8275
7600
Papers discussed in this category
Semin. Arthritis Rheum., 2020 Mar 19
RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.
Related Topics
Rheumatology
Rheumatoid Arthritis
Methotrexate
Hepatitis B
Hepatitis C
Liver disease
Biologics
Pancreatitis
Myositis
IVIG